Displaying items by tag: Perrigo Co plc
MiBiz Growth Report: January 3, 2021
Construction leaders face a mixed bag of concern, hope heading into 2021
Recent year-end reports on non-residential construction activity softening and a plunging average project backlog are giving West Michigan construction leaders some reason for concern going into 2021.
Perrigo seeks $4.1M in tax incentives for planned GR headquarters; Holland expansion moves forward
GRAND RAPIDS — Perrigo Co. plc is seeking a 12-year incentive agreement estimated at $4.1 million in total property tax savings for its plans to relocate its North American headquarters to downtown.
9 Projects to watch in West Michigan
The COVID-19 pandemic has brought ups and downs for West Michigan’s construction industry — activity and competition has increased in areas like school bond projects, while the hospitality and office sectors saw major slowdowns.
MSU officials see close alignment with Perrigo’s planned GR headquarters
GRAND RAPIDS — Perrigo Co. plc’s planned North America headquarters in downtown Grand Rapids adds a major new player to the Medical Mile academic, research and health care cluster as well as a potential new partner for Michigan State University.
Perrigo CEO sees Grand Rapids Medical Mile as potential ‘Silicon Valley of self-care’
GRAND RAPIDS — Executives at Perrigo Co. plc believe the company’s new North American headquarters will fit in neatly with the city of Grand Rapids’ burgeoning health care sector along Medical Mile.
Perrigo to relocate North American HQ to downtown Grand Rapids
GRAND RAPIDS — Perrigo Co. plc is relocating its North American corporate headquarters to downtown Grand Rapids, MiBiz has learned.
MiBiz Growth Report: August 16, 2020
MiBiz growth report for August 16, 2020.
Perrigo inks deal to buy 3 brands from Sanofi
ALLEGAN — Perrigo Co. plc intends to buy three skin care and hair loss brands from French pharmaceutical company Sanofi.
Perrigo reports boost in Q2 sales
Perrigo Co. plc grew sales more than 6 percent in the second quarter as earlier high demand eased for some medications during the COVID-19 pandemic.